Skip to content

2026 ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE • ORLANDO, FL

FRIDAY, MAY 22- SUNDAY, MAY 24
The Chandler Project
  • ABOUTExpand
    • MISSION
    • FOUNDER’S STORY
  • COMMUNITYExpand
    • Friends of Chandler
    • RARE-X
    • PICNIC HEALTH
    • THE MIGHTY
  • CONDITIONSExpand
    • ACHONDROPLASIA
    • HYPOCHONDROPLASIA
    • PSEUDOACHON.
    • SEDC
  • PHARMACHONExpand
    • Nurse Vic’s Notes
  • RESEARCHExpand
    • NEWS
    • STUDIES & TRIALS
    • Treatments & PipelinesExpand
      • BioMarin Pharmaceutical
      • QED Therapeutics
      • Ascendis Pharma
      • Tyra Biosciences
      • SANOFI
      • INNOSKEL
      • PFIZER (NULL)
  • CONTACT
Instagram Facebook Facebook Group Linkedin Email
The Chandler Project

NOONAN SYNDROME

  • BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
    BioMarin · Vosoritide · Voxzogo

    BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

    SOURCE Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal Conditions New Data Highlight…

    Read More BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society MeetingContinue

  • First clinical trial of vosoritide for children with hypochondroplasia shows increased growth
    Clinical Trial · Hypochondroplasia · Vosoritide

    First clinical trial of vosoritide for children with hypochondroplasia shows increased growth

    SOURCE: Children’s National Hospital – Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of…

    Read More First clinical trial of vosoritide for children with hypochondroplasia shows increased growthContinue

Copyright © 2026 · The Chandler Project · Hello You Designs

translate ?
Scroll to top
 

Loading Comments...
 

    • ABOUT
      • MISSION
      • FOUNDER’S STORY
    • COMMUNITY
      • Friends of Chandler
      • RARE-X
      • PICNIC HEALTH
      • THE MIGHTY
    • CONDITIONS
      • ACHONDROPLASIA
      • HYPOCHONDROPLASIA
      • PSEUDOACHON.
      • SEDC
    • PHARMACHON
      • Nurse Vic’s Notes
    • RESEARCH
      • NEWS
      • STUDIES & TRIALS
      • Treatments & Pipelines
        • BioMarin Pharmaceutical
        • QED Therapeutics
        • Ascendis Pharma
        • Tyra Biosciences
        • SANOFI
        • INNOSKEL
        • PFIZER (NULL)
    • CONTACT
    Search